Philippe Huot-Marchand - INVENTIVA S.A

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 27 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial

Diana Barb,Srilaxmi Kalavalapalli,Eddison Godinez Leiva,Fernando Bril,Philippe Huot-Marchand, Lucile Lucile, Jens Rosenberg,Jean-Louis Junien,Pierre Broqua,Andrea Ortiz Rocha,Romina Lomonaco,Michael Cooreman,Kenneth Cusi

crossref（2024）

引用0浏览0引用

LANIFIBRANOR REVERSES INSULIN RESISTANCE AND IMPROVES GLUCOSE AND LIPID METABOLISM IN PATIENTS WITH TYPE 2 DIABETES (T2D) AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

Diana Barb,Srilaxmi Kalavalapalli,Eddison GodinezLeiva,Fermando Bril,Philippe Huot-Marchand,Lucile Dzen,Jean Louis Junien,Pierre Broqua,Andrea Ortiz Rocha,Romina Lomonaco,Michael Cooreman,Kenneth Cusi

HEPATOLOGYno. 2 (2024): E64-E65

引用0浏览0引用

The Pan-Ppar Agonist Lanifibranor Improves Cardiometabolic Health in Patients with Metabolic Dysfunction-Associated Steatohepatitis

Michael P. Cooreman,Javed Butler,Robert P. Giugliano,Faiez Zannad,Lucile Dzen,Philippe Huot-Marchand,Martine Baudin, Daniel R. Beard,Jean-Louis Junien,Pierre Broqua,Manal F. Abdelmalek,Sven M. Francque

NATURE COMMUNICATIONSno. 1 (2024)

引用0浏览0WOSNATURE引用

LANIFIBRANOR-ASSOCIATED ADIPONECTIN INCREASE CORRELATES WITH IMPROVEMENT OF HISTOLOGICAL AND SERUM MARKERS OF NASH SEVERITY BOTH IN TERMS OF ACTIVITY AND FIBROSIS

Michael Cooreman,Manal F. Abdelmalek,Philippe Huot-Marchand,Lucile Dzen,Martine Baudin,Jean Louis Junien,Pierre Broqua,Sven Francque

HEPATOLOGY (2023): S1204-S1205

引用0浏览0引用

Early aminotransferase improvement in the phase 2b NATIVE study is predictive of response pattern of liver histology as well as hepatic and cardiometabolic health markers at the end of treatment in patients with non-cirrhotic NASH

Quentin Anstee,Philippe Huot-Marchand,Lucile Dzen,Jean-Louis Junien,Pierre Broqua,Sven Francque,Manal Abdelmalek,Michael Cooreman,Stephen Harrison

JOURNAL OF HEPATOLOGY (2023): S651-S651

引用0浏览0引用

LANIFIBRANOR IMPROVES LIVER HISTOLOGY AND MARKERS OF CARDIOMETABOLIC HEALTH IN PATIENTS WITH NASH INDEPENDENT OF PNPLA3 GENOTYPE: A RETROSPECTIVE ANALYSIS OF THE NATIVE STUDY

Louis H. Griffel,Sven Francque,Manal F. Abdelmalek,Philippe Huot-Marchand, Lucile Dzen Martine Baudin,Jean Louis Junien,Pierre Broqua,Michael Cooreman

HEPATOLOGY (2023): S1202-S1203

引用0浏览0引用

844-P: Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated with Responses in Adiponectin Levels

Louis Griffel,SVEN FRANCQUE,MANAL F. ABDELMALEK,PHILIPPE HUOT-MARCHAND,LUCILE DZEN,Martine Baudin, JEAN L. JUNIEN,PIERRE BROQUA,MICHAEL P. COOREMAN

Diabetesno. Supplement_1 (2023)

引用0浏览0引用

Correlation Between Severity of Hepatic Steatosis and Markers of Cardiometabolic Health, and Effect of Lanifibranor Therapy in Patients with Non-Cirrhotic NASH

Michael Cooreman,Sven Francque,Philippe Huot-Marchand,Lucile Dzen,Martine Baudin,Jean-Louis Junien,Pierre Broqua,Manal Abdelmalek

Journal of Hepatology（2023）

引用0浏览0引用

The Pan-Ppar Agonist Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH Independent of Weight Change

Michael Cooreman,Sven Francque,Martine Baudin,Philippe Huot-Marchand,Lucile Dzen,Jean-Louis Junien,Pierre Broqua,Manal Abdelmalek

JOURNAL OF HEPATOLOGY（2022）

引用0浏览0引用

Pharmacological inhibition of cullin-ring e3 ligases improves hepatic insulin resistance, hyperglycemia and hepatic steatosis in obese mice

Michael Cooreman,Sven M. Francque,Philippe Huot-Marchand,Lucile Dzen,Martine Baudin,Jean-Louis Junien,Pierre Broqua,Manal F. Abdelmalek

HEPATOLOGY（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn